Literature DB >> 27831507

Surgical management of complex residual masses following systemic chemotherapy for metastatic testicular germ cell tumours.

A Heidenreich1, F Haidl1, P Paffenholz1, Ch Pape2, U Neumann3, D Pfister1.   

Abstract

Background: Post-chemotherapy retroperitoneal lymphadenectomy (PC-RPLND) represents the treatment of choice in patients with residual masses following chemotherapy for metastatic germ cell tumours. Involvement of major retroperitoneal vessels or thoracic/lumbar spine is rare and challenging but needs complete resection for curative intent. We report on our experience in the management of such complex cases. Patients and methods: A total of 185 patients underwent PC-RPLND and we identified 25 (13.5%) patients who needed complex adjunctive vascular (n = 16, 8.6%), skeletal (n = 5, 2.7%) and pancreaticoduodenal (n = 4, 2.2%) surgeries. We performed a retrospective analysis of treatment-associated complications according to the Clavien-Dindo classification. Progression-free, cancer-specific and overall survival was calculated.
Results: All patients were of intermediate/poor prognosis according to IGCCCG. Median tumour diameter at time of surgery was 18.6 (9.0-35) cm. Sixteen (8.6%) underwent vascular surgery including aortic resection and replacement, complete or partial resection of the inferior vena cava with thrombectomy, and resection and replacement of the iliac vessels. In five patients, 1-2 metastatic lumbar vertebral bodies were resected, stabilized and replaced. Four patients underwent en-bloc resection of a suprahilar mass with pancreas and duodenum. Pathohistology revealed vital cancer in five patients; teratoma and malignant somatic transformation was identified in 12 and 6 patients, respectively. Complications occurred more often in the group of complex RPLND (41.7 versus 7.2%, P = 0.02) with the majority representing grade I-IIa. After a median follow-up of 28.5 months, four patients developed recurrent disease and one patient died of the disease. Conclusions: Few patients with advanced GCT need complex vascular, skeletal or intestinal surgery in an interdisciplinary setting with good functional and oncological outcome. Due to the complexity, treatment should be performed at specialized centres.
© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  aortic replacement; inferior vena cava surgery; pancreaticoduodenal surgery; post-chemotherapy retroperitoneal lymph node dissection; skeletal surgery; testis cancer

Mesh:

Year:  2017        PMID: 27831507     DOI: 10.1093/annonc/mdw605

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  11 in total

1.  Recent developments in the management of germ cell tumors.

Authors:  Pavlos Msaouel; Mehmet A Bilen; Miao Zhang; Matthew Campbell; Jennifer Wang; Shi-Ming Tu
Journal:  Curr Opin Oncol       Date:  2017-05       Impact factor: 3.645

2.  Survival Outcomes of Patients With Primary Mediastinal Germ Cell Tumors: A Retrospective Single-institutional Experience.

Authors:  Hiroshi Yaegashi; Takahiro Nohara; Kazuyoshi Shigehara; Kouji Izumi; Yoshifumi Kadono; Tomoyuki Makino; Kaname Yamashita; Koushiro Ohtsubo; Hiroko Ikeda; Atsushi Mizokami
Journal:  Cancer Diagn Progn       Date:  2022-05-03

3.  Preoperative clinical and radiographic predictors of major vascular surgery in patients with testicular cancer undergoing post-chemotherapy residual tumor resection (PC-RPLND).

Authors:  Alessandro Nini; Matthias Boschheidgen; Andreas Hiester; Christian Winter; Gerald Antoch; Lars Schimmöller; Peter Albers
Journal:  World J Urol       Date:  2021-11-03       Impact factor: 4.226

Review 4.  [When is surgical resection of metastases in testicular germ cell tumors indicated and is there a scientific basis?]

Authors:  A Heidenreich; P Paffenholz; F Haidl; D Pfister
Journal:  Urologe A       Date:  2017-05       Impact factor: 0.639

Review 5.  [Limits of surgery in uro-oncology].

Authors:  A Heidenreich
Journal:  Urologe A       Date:  2018-09       Impact factor: 0.639

6.  Radiomics allows for detection of benign and malignant histopathology in patients with metastatic testicular germ cell tumors prior to post-chemotherapy retroperitoneal lymph node dissection.

Authors:  Bettina Baessler; Tim Nestler; Daniel Pinto Dos Santos; Pia Paffenholz; Vikram Zeuch; David Pfister; David Maintz; Axel Heidenreich
Journal:  Eur Radiol       Date:  2019-12-11       Impact factor: 5.315

Review 7.  Testicular teratomas: a growing problem?

Authors:  Wojciech Michalski; Joanna Jonska-Gmyrek; Grazyna Poniatowska; Jakub Kucharz; Pawel Stelmasiak; Karol Nietupski; Malgorzata Sadowska; Tomasz Demkow; Pawel Wiechno
Journal:  Med Oncol       Date:  2018-10-26       Impact factor: 3.064

8.  Intraoperative and early postoperative complications in postchemotherapy retroperitoneal lymphadenectomy among patients with germ cell tumors using validated grading classifications.

Authors:  Eric C Umbreit; Andrew G McIntosh; Chalairat Suk-Ouichai; Luis A Segarra; Levi C Holland; Bryan M Fellman; Stephen B Williams; Arun Z Thomas; Shi-Ming Tu; Curtis A Pettaway; Louis L Pisters; John F Ward; Christopher G Wood; Jose A Karam
Journal:  Cancer       Date:  2020-09-17       Impact factor: 6.921

9.  Preservation of Ejaculatory Function After Postchemotherapy Retroperitoneal Lymph Node Dissection (PC-RPLND) in Patients With Testicular Cancer: Template vs. Bilateral Resection.

Authors:  Andreas Hiester; Alessandro Nini; Anna Fingerhut; Robert Große Siemer; Christian Winter; Peter Albers; Achim Lusch
Journal:  Front Surg       Date:  2019-01-17

10.  Additional surgical procedures and perioperative morbidity in post-chemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer in two intermediate volume hospitals.

Authors:  Joost M Blok; Richard P Meijer; Henk G van der Poel; Axel Bex; Jeanette van Vooren; Japke J van Urk; Simon Horenblas; J L H Ruud Bosch
Journal:  World J Urol       Date:  2020-05-05       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.